News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vertex Pharmaceuticals (MA) (VRTX) Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs


7/30/2013 6:40:58 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2013. Vertex reported total second quarter 2013 revenues of $311 million, including net product revenues of $99 million from KALYDECOTM (ivacaftor) and $156 million from INCIVEKĀ® (telaprevir). The GAAP net loss attributable to Vertex was $(57.2) million, or $(0.26) per share, for the second quarter of 2013, including certain charges of $51.0 million, comprised primarily of stock-based compensation expense.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES